Market Place
Sourcing Support
Avidity Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
21 May 2025 //
PR NEWSWIRE
Avidity Biosciences Joins Investor Conference
01 Apr 2025 //
PR NEWSWIRE
Avidity Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
21 Feb 2025 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
20 Jan 2025 //
PR NEWSWIRE
Avidity Biosciences Reports Q3 2024 Financials & Highlights
07 Nov 2024 //
PR NEWSWIRE
Avidity Raises Awareness for National Muscular Dystrophy Awareness Month
05 Sep 2024 //
PR NEWSWIRE
Life Science Cares San Diego Expands Partnership With Avidity Biosciences
27 Aug 2024 //
BUSINESSWIRE
Avidity Biosciences Announces Proposed Public Offering of Common Stock
13 Aug 2024 //
PR NEWSWIRE
Analysts dig into details of Avidity`s DMD win, revealing nuances in strong data
12 Aug 2024 //
FIERCE BIOTECH
Avidity Biosciences Announces Inducement Grants Under Nasdaq Rule
22 Jul 2024 //
PR NEWSWIRE
Avidity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Jun 2024 //
PR NEWSWIRE
Avidity Biosciences Partners With FSHD Society For World FSHD Day Awareness
20 Jun 2024 //
PR NEWSWIRE
Avidity Biosciences Closes Upsized Public Offering Of Common Stock
17 Jun 2024 //
PR NEWSWIRE
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
13 Jun 2024 //
PR NEWSWIRE
Avidity Biosciences to Participate in Upcoming Investor Conferences
27 Mar 2024 //
PRESS RELEASE
Avidity accelerates DM1 Phase III trial on the heels of further positive data
04 Mar 2024 //
PRESS RELEASE
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
29 Feb 2024 //
PRESS RELEASE
BMS Expands Cardio Partnership with Avidity in Potential $2.3B Deal
29 Nov 2023 //
BIOSPACE
Avidity says FDA has `eased` partial hold on lead asset
18 May 2023 //
FIERCE BIOTECH
Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Apr 2023 //
PR NEWSWIRE
Avidity Biosciences Stock Soars On New RNA Data
16 Dec 2022 //
BIOSPACE
Avidity clamors for $150M raise on heels of positive data readout
15 Dec 2022 //
ENDPTS
Avidity Announces Pricing of Upsized Public Offering of Common Stock
15 Dec 2022 //
PRNEWSWIRE
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
15 Dec 2022 //
PRNEWSWIRE
Avidity pushes new phase 1/2 data as FDA hold remains in place
14 Dec 2022 //
FIERCEBIOTECH
Avidity Announces Positive AOC 1001 Phase 1/2 MARINA Data
14 Dec 2022 //
PRNEWSWIRE
Avidity Biosciences Reports3Q 2022 Financial Results and Recent Highlights
08 Nov 2022 //
PRNEWSWIRE
Avidity Biosciences Announces Phase 1/2 EXPLORE44 Trial of AOC 1044
11 Oct 2022 //
PRNEWSWIRE
Avidity Biosciences Announces the Phase 1/2 FORTITUDE Trial of AOC 1020
29 Sep 2022 //
BENZINGA
FDA puts partial hold on Avidity`s lead trial over adverse event
28 Sep 2022 //
FIERCEBIOTECH
Avidity Engages with Patient During Muscular Dystrophy Awareness Month
07 Sep 2022 //
PRNEWSWIRE
Avidity Biosciences to Participate in Upcoming Investor Conferences
01 Sep 2022 //
PRESS RELEASE
Avidity Biosciences Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
PRNEWSWIRE
Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
02 Aug 2022 //
PRNEWSWIRE
Avidity Biosciences Reports First Quarter 2022 Financial Results
10 May 2022 //
PRNEWSWIRE
Avidity Bio Expands Role of Michael MacLean to CFO, CBO
05 Apr 2022 //
PRNEWSWIRE
Avidity Bio says Upcoming Presentations at the 2022 MDA
07 Mar 2022 //
PRNEWSWIRE
Avidity Biosciences Reports Q4 and Year-End 2021 Financial Results
01 Mar 2022 //
PRNEWSWIRE
Avidity Biosciences Honors Rare Disease Day®
28 Feb 2022 //
PRNEWSWIRE
Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer
23 Feb 2022 //
PRNEWSWIRE
Avidity Biosciences Highlights FSHD Program at Virtual Investor &Analyst Event
09 Dec 2021 //
BIOSPACE
Avidity Reports Q3 2021 Financial Results and Recent Highlights
09 Nov 2021 //
PRNEWSWIRE
Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate
04 Nov 2021 //
PRNEWSWIRE
Avidity Biosciences Announces Changes to its Board of Directors
25 Aug 2021 //
PRNEWSWIRE
European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001
24 Aug 2021 //
PRNEWSWIRE
Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network
16 Aug 2021 //
PR NEWSWIRE
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
02 Aug 2021 //
PRNEWSWIRE
Avidity Reports Q1 2021 Financial Results and Recent Highlights
12 May 2021 //
PRNEWSWIRE
Avidity Biosciences to Present Oral Presentation on AOC 1001
16 Apr 2021 //
BIOSPACE
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trial for BAT1308
21 Jan 2021 //
BUSINESSWIRE
#JPM21: Avidity CSO Art Levin runs full speed to the clinic with `dream`
14 Jan 2021 //
ENDPTS
Avidity Announces 2021 Pipeline Updates and Research Collaboration MyoKardia
08 Jan 2021 //
PRNEWSWIRE
Avidity Biosciences Announces Addition to the Nasdaq Biotechnology Index
22 Dec 2020 //
PRNEWSWIRE
Avidity Biosciences Announces Addition to the Nasdaq Biotechnology Index
22 Dec 2020 //
PRNEWSWIRE
Avidity Biosciences Announces Addition to the Nasdaq Biotechnology Index
22 Dec 2020 //
PRNEWSWIRE
Avidity Biosciences Enters into Collaboration to Study Myotonic Dystrophy Type 1
08 Sep 2020 //
BIOSPACE
Avidity tops up IPO at $298M; Bristol Myers keeps a Celgene discovery pact alive
17 Jun 2020 //
ENDPTS
Avidity Biosciences Announces Closing of Initial Public Offering
16 Jun 2020 //
PRNEWSWIRE
Avidity Biosciences Announces Pricing of Initial Public Offering
11 Jun 2020 //
PRNEWSWIRE
Muscle disorder biotech Avidity shoots for $100M IPO
26 May 2020 //
FIERCE BIOTECH
